A new study finds that the incidence of cancer in high-income counties has spiked higher than in low-income counties, but the wealthier areas saw their cancer mortality rates decrease more, which could indicate that overdiagnosis is occurring among well-off populations.
A new study finds that the incidence of cancer in high-income counties has spiked higher than in low-income counties, but the wealthier areas saw their cancer mortality rates decrease more, which could indicate that overdiagnosis is occurring among well-off populations.
According to the research published in New England Journal of Medicine, numerous studies have explored the complex interplay between health and socioeconomic status. Although prior investigations have found that higher income is linked to greater longevity, this association may not be because the wealthy are receiving more healthcare. To the contrary, people with greater financial resources may be at risk of overutilization, which can have a range of downstream health consequences.
In particular, excessive cancer screening can result in overdiagnosis and avoidable services. Cancers vary in their sensitivity to observational intensity, which is an interplay of factors like screening frequency, detection power, and abnormality threshold. “Observational intensity can have a dramatic effect on the apparent amount of disease—particularly for cancers that have a substantial reservoir of indolent, subclinical forms,” the researchers wrote.
To assess incidence and mortality trends for 4 of these cancers sensitive to observational sensitivity (breast, prostate, thyroid cancer, and melanoma), the researchers employed data from a national epidemiology database. Combined with US Census data on county-level median income, they analyzed the differences in incidence and mortality in high-income counties (median family incomes more than $75,000) and low-income counties (median family incomes less than $40,000).
The analysis, which was restricted to white people to avoid any potential confounding effects from race, found that the incidence of these cancers had risen in both groups of counties since 1975, but the high-income areas saw a much sharper increase in incidence. They hypothesized that wealthier people are exposed to higher levels of observational intensity, meaning they are screened more frequently by more sensitive tests and receive more follow-up testing and biopsies, leading to higher rates of cancers found and reported.
Cancer mortality was similar in both types of counties over the years, as it has shown a steady decrease, potentially due to improvements in therapies. Since 1990, mortality has declined by 40% in high-income counties and 25% in low-income ones, which the authors attributed to better access to innovative treatments in well-off areas.
The researchers hypothesized that the differing incidences of cancer in high- and low-income areas could occur because wealthier people expect and demand more testing, since they can afford it. Additionally, fee-for-service models may incentivize health systems to provide more testing options for richer customers, thus boosting their revenues. Together, these factors could create “a mutually reinforcing cycle that promotes testing as the path to health.”
As the healthcare system attempts to eliminate waste and low-value service, excessive screening and overutilization are important targets, the study authors write. If these tests and services provide little value and cause harm to patients, reducing the frequency of overdiagnosis and its downstream costs could cut spending and improve health.
The researchers recommended transitioning to models like accountable care organizations, which discourage the delivery of low-value care. They also argue that clinicians should refocus their conversations with patients to emphasize total wellness instead of early detection.
“Although we have much to offer people who are sick or injured, physicians have overstated medicine’s role in promoting health,” they concluded. “In so doing, we may have unintentionally devalued the role of more important determinants of health for people at every income level—healthy food, regular movement, and finding purpose in life.”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More